Tag: <span>MT-3921 trial</span>

Home / MT-3921 trial
Post

Phase 2 Trial of MT-3921 initiated for treatment of spinal cord injury

OSAKA UNIVERSITY Mitsubishi Tanabe Pharma Corporation (MTPC, Head Office: Chuo-ku, Osaka; President & Representative Director, CEO: Hiroaki Ueno) and Professor Toshihide Yamashita at the Department of Molecular Neuroscience and Department of Neuro-Medical Science, Osaka University Graduate School of Medicine, announced today that MTPC’s research and development subsidiary in the US, Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)...